ClinicalTrials.gg
CompletedNCT04238819Updated Mar 2, 2026Results posted

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

A Phase 1/2 interventional study of Abemaciclib and Irinotecan in Relapsed Solid Tumor and Refractory Solid Tumor, sponsored by Eli Lilly and Company. Completed at 25 sites in 8 countries. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing temozolomide in Sarcoma, Ewing — 3 open to participants now, 5 under way, none of them phase 3. Temozolomide · Sarcoma, Ewing.

Enrollment
6th of 14
47 · median 39
Started
2020
the only one that year
Phase 1/2
3 of 14
1 open now
Registered
10th of 14
by date
Lead sponsor
2 of 14
Eli Lilly and Company

Among the 14 studies testing temozolomide in Sarcoma, Ewing, this one is the 6th largest by enrollment, is the only one that started in 2020, is one of 3 in phase 1/2, and was the 10th registered.

Sarcoma, Ewing

250 studies on the registry are indexed under Sarcoma, Ewing; 69 are open to participants now.

Browse Sarcoma, Ewing studies →

Open to participants now

3 of the 14 studies testing temozolomide in Sarcoma, Ewing are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 58 Sarcoma, Ewing studies recruiting now, 19 (33%) set no upper age limit and 36 (62%) stop at 75 or younger; 49 take children under 18; 2 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing temozolomide in Sarcoma, Ewing, or all of them as a file.
02

Study summary

The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did not respond or grew during other anti-cancer treatment. For each participant, the study is estimated to last up to 2 years.

03

Conditions studied

  • Relapsed Solid Tumor
  • Refractory Solid Tumor

Keywords

  • CDK4
  • CDK6
  • Ewing's sarcoma
  • Neuroblastoma
  • Recurrent neuroblastoma
  • Malignant rhabdoid tumor
  • Rhabdomyosarcoma
  • Osteosarcoma
  • Brain tumor
  • Glioblastoma
  • Malignant glioma
  • Diffuse intrinsic pontine glioma
  • Medulloblastoma
  • Ependymoma
  • Solid tumor
  • High-grade glioma
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parts A and B only:

    • Participants must be less than or equal to (≤)18 years of age.
    • Body weight greater than or equal to (≥)10 kilograms and body surface area (BSA) ≥0.5
    • Participants with any malignant solid tumor (excluding lymphoma), including central nervous system tumors, that have progressed on standard therapies.
    • For sites that are actively enrolling Parts B and C, participants with neuroblastoma who are eligible for Part C will be excluded from Part B unless approved by Lilly CRP/CRS.
  • Part C only:

    • Participants must be less than (\<) 21 years of age.
    • Participants have a BSA ≥0.2 m².
    • Participants with first relapse/refractory neuroblastoma.
  • All Parts

    • Participants must have measurable or evaluable disease by v1.1 or RANO.
    • A Lansky score ≥50 for participants \<16 years of age or score ≥50 for participants ≥16 years of age.
    • Participants must have discontinued all previous treatments for cancer or agents and must have recovered from the acute effects to Grade ≤1 at the time of enrollment.
    • Able to swallow and/or have a gastric/nasogastric tube.
    • Adequate hematologic and organ function ≤2 weeks (14 days) prior to first dose of study drug.
    • Females of must have negative urine or serum pregnancy test at baseline (within 7 days prior to starting treatment).
    • Female participants of reproductive potential must agree to use highly effective precautions during the trial. For abemaciclib, females should use contraception for at least 3 weeks following the last abemaciclib. For other study drugs, highly effective contraceptive precautions (and avoiding sperm donation) must be used according to their label.
    • of at least 8 weeks and able to complete at least 1 cycle of treatment.
    • Caregivers and participants willing to make themselves available for the duration of the trial.

Exclusion criteria

Exclusion Criteria:

  • Received allogenic bone marrow or solid organ transplant.
  • Received .
  • Intolerability or to any of the study treatments or its components.
  • Diagnosed and/or treated additional within 3 years prior to enrollment that may affect the interpretation of results, with the exception of curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected in situ cervical and/or breast cancers.
  • Pregnant or breastfeeding.
  • Active systemic infections.
  • Serious and/or uncontrolled preexisting medical condition(s) that would preclude participation in this study.
  • Parts A and C only: Have a bowel obstruction.
  • Prior treatment with drugs known to be strong inhibitors or inducers of isoenzyme cytochrome P450 3A () or strong inhibitors of uridine diphosphate-glucuronosyl transferase 1A1 (UGT1A1) if the treatment cannot be discontinued or switched to a different medication at least 5 half-lives prior to starting study drug.
  • Received prior treatment with cyclin-dependent kinase (CDK) 4 \& 6 inhibitor.
  • Part C only: Received prior systemic therapy for neuroblastoma.
  • Part C only, have received prior anti-GD2 therapy during induction phase.
  • Currently enrolled in any other clinical study involving an product or non-approved use of a drug or device.
  • Has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Part A Cohort A1

    Participants received: * Abemaciclib: 70 mg/m², administered orally twice daily (BID). * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide

  • Experimental
    Part A Cohort A-1

    Participants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide

  • Experimental
    Part B Cohort B1

    Participants received: * Abemaciclib: 70 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Temozolomide

  • Experimental
    Part B Cohort B2

    Participants received: * Abemaciclib: 90 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Temozolomide

  • Experimental
    Part B Cohort B3

    Participants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Temozolomide

  • Experimental
    Part B Cohort B5

    Participants received: * Abemaciclib: 115 mg/m², administered orally BID. * Temozolomide: 150 mg/m²/day, administered orally on Days 1-5 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Temozolomide

  • Experimental
    Part C Cohort C1

    Participants received: * Abemaciclib: 55 mg/m², administered orally BID. * Irinotecan: 50 mg/m²/day, administered IV on Days 1-5 of each cycle. * Temozolomide: 100 mg/m²/day, administered orally on Days 1-5 of each cycle. * Dinutuximab: 17.5mg/m²/day, administered IV on Days 2-5 of each cycle. * Granulocyte-macrophage colony-stimulating factor (GM-CSF): 250 μg/m²/day, administered subcutaneously (SC) on Days 6-12 of each cycle. Treatment continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Each cycle lasted 21 days.

    Drug: Abemaciclib · Drug: Irinotecan · Drug: Temozolomide · Drug: Dinutuximab · Drug: GM-CSF

Interventions

06

What researchers measure

Primary outcomes

  1. Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)

    The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

    Time frame: Cycles 1 and 2 (21 Day Cycles)

  2. Number or Participants With Dose Limiting Toxicities (DLTs) in Part A

    DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hour (h) * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 h * G3 mucositis/stomatitis lasting \<72 h * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 h, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

    Time frame: Cycle 1 (21 Day Cycle)

  3. Maximum Tolerated Dose (MTD) of Abemaciclib in Part A

    The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

    Time frame: Cycle 1 (21 Days)

  4. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A

    PK: (AUC0-tlast) was reported.

    Time frame: Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

  5. PK: (AUC0-tlast) of Irinotecan in Part A

    PK: AUC0-tlast) was reported.

    Time frame: 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

  6. PK: (AUC0-tlast) of Temozolomide in Part A

    PK: AUC0-tlast was reported.

    Time frame: 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

  7. RP2D of Abemaciclib in Combination With Temozolomide (Part B)

    The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

    Time frame: Cycles 1 and 2 (21 Day Cycles)

  8. Number or Participants With DLTs in Part B

    A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hr * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 hr * G3 mucositis/stomatitis lasting \<72 hr * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 hr, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

    Time frame: Cycle 1 (21 Day Cycle)

  9. MTD of Abemaciclib in Part B

    The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

    Time frame: Cycle 1 (21 Days)

  10. PK: AUC0-tlast of Abemaciclib in Part B

    PK: AUC0-tlast was reported.

    Time frame: Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

  11. PK: AUC0-tlast of Temozolomide in Part B

    PK: AUC0-tlast was reported.

    Time frame: 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)

  12. Number of Participants With Overall Response Rate (ORR) in Part C.

    ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC). * CR is defined as complete response in all response components: * Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors * Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved * Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD

    Time frame: Date of first dose to disease progression or death (Up to 25 Months)

Secondary outcomes

  1. Percentage of Participants With Overall Response Rate (ORR): Part A

    ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

    Time frame: Date of first dose to disease progression or death (Up to 25 Months)

  2. Percentage of Participants With ORR: Part B

    ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

    Time frame: Date of first dose to disease progression or death (Up to 25 Months)

  3. Duration of Response (DoR): Parts A and B.

    DoR is the time between first evidence of CR or PR and disease progression or death due to any cause. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

    Time frame: Date of first evidence of a CR or PR to date of objective disease progression or death due to any cause (Up to 25 Months)

  4. Duration of Response (DoR): Part C

    DoR is the time between first evidence of CR, PR or MR and disease progression or death due to any cause. CR, PR, and MR was as per International Neuroblastoma Response Criteria (INRC). \- CR is defined as complete response in all response components: Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1 component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD

    Time frame: Date of first evidence of a CR, PR, or MR to date of objective disease progression or death due to any cause (Up to 25 Months)

  5. Percentage of Participants With Clinical Benefit Rate (CBR): Part A

    The CBR is the percentage of participants with a best response of CR or PR, or Stable Disease (SD) for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

    Time frame: Date of first dose to disease progression or death due to any cause (Up to 25 Months)

  6. Percentage of Participants With CBR: Part B

    The CBR is the percentage of participants with a best response of CR or PR, or SD for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

    Time frame: Date of first dose to disease progression or death due to any cause (Up to 25 Months)

  7. Percentage of Participants With Disease Control Rate (DCR): Part A

    DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

    Time frame: Date of first dose to measured progressive disease (Up to 25 Months)

  8. Percentage of Participants With DCR: Part B

    DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

    Time frame: Date of first dose to measured progressive disease (Up to 25 Months)

  9. Progression-Free Survival (PFS): Part C

    Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.

    Time frame: Date of first dose to progressive disease or death (Up to 25 Months)

  10. Abemaciclib Tablet Acceptability

    Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - " Was it easy or difficult for the study subject to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.

    Time frame: Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (21 Day Cycles)

07

Results

Posted Aug 6, 2025

Participant flow

Participant flow — Overall Study
MilestonePart A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1
Started713393111
Received at least one dose of study drug713393111
Completed712373100
Not completed0102011
Withdrew: Discontinued study treatment, but follow-up visit was not completed due to primary study condition0000010
Withdrew: Withdrawal by parent/subject0102001

Outcome measures

PrimaryRecommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)

The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 50 mg/m²/day irinotecan and 100 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

Time frame:
Cycles 1 and 2 (21 Day Cycles)
Reported as:
Number · milligrams/squared meters (mg/m²) BID
Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)
milligrams/squared meters (mg/m²) BIDPart A - Abemaciclib
Recommended Phase 2 Dose (RP2D) of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A)55
PrimaryNumber or Participants With Dose Limiting Toxicities (DLTs) in Part A

DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hour (h) * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 h * G3 mucositis/stomatitis lasting \<72 h * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 h, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

Time frame:
Cycle 1 (21 Day Cycle)
Reported as:
Count of participants · Participants
Number or Participants With Dose Limiting Toxicities (DLTs) in Part A
ParticipantsPart A Cohort A1Part A Cohort A-1
Number or Participants With Dose Limiting Toxicities (DLTs) in Part A31
PrimaryMaximum Tolerated Dose (MTD) of Abemaciclib in Part A

The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

Time frame:
Cycle 1 (21 Days)
Reported as:
Number · mg/m² BID
Maximum Tolerated Dose (MTD) of Abemaciclib in Part A
mg/m² BIDPart A - Abemaciclib
Maximum Tolerated Dose (MTD) of Abemaciclib in Part A55
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A

PK: (AUC0-tlast) was reported.

Time frame:
Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Tlast (AUC0-tlast) of Abemaciclib in Part A
nanogram *hour per milliliter (ng*h/mL)Part A: 70 mg/m² AbemaciclibPart A: 55 mg/m² Abemaciclib
Cycle 1, Day 1730 ± 33534 ± 116
Cycle 2, Day 1NA ± NA757 ± 100
PrimaryPK: (AUC0-tlast) of Irinotecan in Part A

PK: AUC0-tlast) was reported.

Time frame:
2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Reported as:
Geometric mean · ng*h/mL
PK: (AUC0-tlast) of Irinotecan in Part A
ng*h/mLPart A: 50 mg/m²/Day Irinotecan
Cycle 1, Day 11450 ± 37
Cycle 2, Day 11240 ± 58
PrimaryPK: (AUC0-tlast) of Temozolomide in Part A

PK: AUC0-tlast was reported.

Time frame:
1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Reported as:
Geometric least squares mean · ng*h/mL
PK: (AUC0-tlast) of Temozolomide in Part A
ng*h/mLPart A: 100 mg/m²/Day Temozolomide
Cycle 1, Day 114400 ± 23
Cycle 2, Day 112200 ± 44
PrimaryRP2D of Abemaciclib in Combination With Temozolomide (Part B)

The RP2D of abemaciclib was determined based on the totality of safety, tolerability, and pharmacokinetic results. RP2D of abemaciclib in combination with 150 mg/m²/day temozolomide on days 1-5 of 21-day cycles was reported.

Time frame:
Cycles 1 and 2 (21 Day Cycles)
Reported as:
Number · mg/m² BID
RP2D of Abemaciclib in Combination With Temozolomide (Part B)
mg/m² BIDPart B - Abemaciclib
RP2D of Abemaciclib in Combination With Temozolomide (Part B)115
PrimaryNumber or Participants With DLTs in Part B

A DLT was 1 of the following adverse events likely related to abemaciclib/combination and fulfils any 1 of the following criteria graded as per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0: * Any non-hematologic Grade (G) ≥3 toxicity, except: * G3 diarrhea lasting \<72 hr * Acute irinotecan-associated diarrhea lasting \<7 days * G≥3 nausea, vomiting, constipation that lasts \<72 hr * G3 mucositis/stomatitis lasting \<72 hr * G3 fever/infection * G≥3 electrolyte abnormality that lasts \<72 hr, is not complicated, and resolves spontaneously or responds to conventional medication; * G≥3 amylase/lipase that is not associated with symptoms/clinical manifestations of pancreatitis; or * AST/ALT elevation resolving to eligibility criteria within 7 days; * Hematologic toxicities considered a DLT: * A \>14-day Cycle 2 delay due to neutropenia/thrombocytopenia * G≥3 thrombocytopenia with significant bleeding; or * G≥ 4 neutropenic fever

Time frame:
Cycle 1 (21 Day Cycle)
Reported as:
Count of participants · Participants
Number or Participants With DLTs in Part B
ParticipantsPart B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5
Number or Participants With DLTs in Part B0101
PrimaryMTD of Abemaciclib in Part B

The MTD was defined as the highest dose level at which less than 33% of participants experienced a DLT.

Time frame:
Cycle 1 (21 Days)
Reported as:
Number · mg/m² BID
MTD of Abemaciclib in Part B
mg/m² BIDPart B - Abemaciclib
MTD of Abemaciclib in Part BNA
PrimaryPK: AUC0-tlast of Abemaciclib in Part B

PK: AUC0-tlast was reported.

Time frame:
Pre-dose, 1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Reported as:
Geometric mean · ng*h/mL
PK: AUC0-tlast of Abemaciclib in Part B
ng*h/mLPart B: 70 mg/m² AbemaciclibPart B: 90 mg/m² AbemaciclibPart B: 115 mg/m² Abemaciclib
Cycle 1, Day 1566 ± 104728 ± 60728 ± 77
Cycle 2, Day 1NA ± NA600 ± 271060 ± 57
PrimaryPK: AUC0-tlast of Temozolomide in Part B

PK: AUC0-tlast was reported.

Time frame:
1, 2.5, 4, and 6 hours post Day 1 dose of Cycle 1 and Cycle 2 (21 Day Cycle)
Reported as:
Geometric least squares mean · ng*h/mL
PK: AUC0-tlast of Temozolomide in Part B
ng*h/mLPart B: 100 mg/m²/Day TemozolomidePart B: 150 mg/m²/Day Temozolomide
Cycle 1, Day 115800 ± 1924300 ± 13
Cycle 2, Day 115700 ± 2121100 ± 43
PrimaryNumber of Participants With Overall Response Rate (ORR) in Part C.

ORR: Number of participants with best response of Complete Response (CR), Partial Response (PR), or Minor Response (MR) per International Neuroblastoma Response Criteria (INRC). * CR is defined as complete response in all response components: * Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors * Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved * Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD

Time frame:
Date of first dose to disease progression or death (Up to 25 Months)
Reported as:
Count of participants · Participants
Number of Participants With Overall Response Rate (ORR) in Part C.
ParticipantsPart C Cohort C1
Number of Participants With Overall Response Rate (ORR) in Part C.1
SecondaryPercentage of Participants With Overall Response Rate (ORR): Part A

ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

Time frame:
Date of first dose to disease progression or death (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Overall Response Rate (ORR): Part A
Percentage of participantsPart A Cohort A1Part A Cohort A-1
Percentage of Participants With Overall Response Rate (ORR): Part A0 (NA to NA)7.7 (0.0 to 22.2)
SecondaryPercentage of Participants With ORR: Part B

ORR: Percentage of participants with best response of CR or PR per Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO). RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

Time frame:
Date of first dose to disease progression or death (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With ORR: Part B
Percentage of participantsPart B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5
Percentage of Participants With ORR: Part B0 (NA to NA)0 (NA to NA)33.3 (0.0 to 86.7)18.2 (0.0 to 41.0)
SecondaryDuration of Response (DoR): Parts A and B.

DoR is the time between first evidence of CR or PR and disease progression or death due to any cause. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO).

Time frame:
Date of first evidence of a CR or PR to date of objective disease progression or death due to any cause (Up to 25 Months)
Reported as:
Median · Months
Duration of Response (DoR): Parts A and B.
MonthsPart A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5
Duration of Response (DoR): Parts A and B.—22.59 (NA to NA)——7.82 (NA to NA)0.03 (NA to NA)
SecondaryDuration of Response (DoR): Part C

DoR is the time between first evidence of CR, PR or MR and disease progression or death due to any cause. CR, PR, and MR was as per International Neuroblastoma Response Criteria (INRC). \- CR is defined as complete response in all response components: Primary Tumor: \<10 mm residual soft tissue primary site and complete resolution of MIBG-avid tumors Soft tissue and bone metastatic response: nonprimary target and nontarget lesions \<10 mm and nodes identified as targets decreased to short axis \<10mm and MIBG-avid update of nonprimary lesions completely resolved Bone marrow response: no tumor infiltration on reassessment; disappearance of all target lesions; * PR is defined as PR in \>1 component and all other components are either CR, minimal disease (MD) (bone marrow only), PR (soft tissue or bone), or not involved (NI) and no components with progressive disease (PD). * MR is defined PR or CR in \>1 component and SD in \>1 component and no component with PD

Time frame:
Date of first evidence of a CR, PR, or MR to date of objective disease progression or death due to any cause (Up to 25 Months)
Reported as:
Median · Months
Duration of Response (DoR): Part C
MonthsPart C Cohort C1
Duration of Response (DoR): Part C1.61 (NA to NA)
SecondaryPercentage of Participants With Clinical Benefit Rate (CBR): Part A

The CBR is the percentage of participants with a best response of CR or PR, or Stable Disease (SD) for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

Time frame:
Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Benefit Rate (CBR): Part A
Percentage of participantsPart A Cohort A1Part A Cohort A-1
Percentage of Participants With Clinical Benefit Rate (CBR): Part A14.3 (0.0 to 40.2)30.8 (5.7 to 55.9)
SecondaryPercentage of Participants With CBR: Part B

The CBR is the percentage of participants with a best response of CR or PR, or SD for at least 6 months. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

Time frame:
Date of first dose to disease progression or death due to any cause (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With CBR: Part B
Percentage of participantsPart B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5
Percentage of Participants With CBR: Part B33.3 (0.0 to 86.7)0 (NA to NA)33.3 (0.0 to 86.7)18.2 (0.0 to 41.0)
SecondaryPercentage of Participants With Disease Control Rate (DCR): Part A

DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

Time frame:
Date of first dose to measured progressive disease (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Control Rate (DCR): Part A
Percentage of participantsPart A Cohort A1Part A Cohort A-1
Percentage of Participants With Disease Control Rate (DCR): Part A71.4 (38.0 to 100.0)53.8 (26.7 to 80.9)
SecondaryPercentage of Participants With DCR: Part B

DCR: Percentage of participants with a best overall response of CR, PR, and SD. RECIST was used for solid tumors and RANO was used for brain tumors. * CR is defined as the disappearance of all target lesions (RECIST) and disappearance of all enhancing measurable and non-measurable disease, no new lesions; stable or improved non-enhancing lesions; and patient must be off corticosteroids and stable or improved clinically (RANO). * PR is defined as a 30% decrease in the sum of diameters of target lesions (RECIST) and \>50% decrease in the sum of products of perpendicular diameters of all measurable enhancing lesions, no progression of non-measurable disease, no new lesions, stable/improved non-enhancing lesions on same or lower dose of corticosteroids and patient is stable or improved clinically (RANO). * SD is neither sufficient shrinkage nor sufficient increase in the size of the tumor.

Time frame:
Date of first dose to measured progressive disease (Up to 25 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With DCR: Part B
Percentage of participantsPart B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5
Percentage of Participants With DCR: Part B33.3 (0.0 to 86.7)55.6 (23.1 to 88.0)100 (100.0 to 100.0)36.4 (7.9 to 64.8)
SecondaryProgression-Free Survival (PFS): Part C

Progression-free survival is measured as the time from first dose of study drug to progressive disease or death, whichever occurs first. PFS for Part C was reported.

Time frame:
Date of first dose to progressive disease or death (Up to 25 Months)
Reported as:
Number · Months
Progression-Free Survival (PFS): Part C
MonthsPart C Cohort C1
Progression-Free Survival (PFS): Part C2.9
SecondaryAbemaciclib Tablet Acceptability

Participants were evaluated for abemaciclib acceptability (palatability and ease of administration) by asking a question - " Was it easy or difficult for the study subject to swallow the abemaciclib today?" Participants or their caregivers or both could respond using the following possible answers: Very difficult, difficult, neither easy nor difficult, easy, or very easy.

Time frame:
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (21 Day Cycles)
Reported as:
Count of participants · Participants
Abemaciclib Tablet Acceptability
ParticipantsPart A Cohort A1 (Caregiver Responses - Cycle 1 Day 1)Part A Cohort A1 (Caregiver Responses - Cycle 1 Day 15)Part A Cohort A1 (Caregiver Responses - Cycle 2 Day 1)Part A Cohort A1 (Participant Responses - Cycle 1 Day 1)Part A Cohort A1 (Participant Responses - Cycle 1 Day 15)Part A Cohort A1 (Participant Responses - Cycle 2 Day 1)Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 1)Part A Cohort A-1(Caregiver Responses - Cycle 1 Day 15)Part A Cohort A-1(Caregiver Responses - Cycle 2 Day 1)Part A Cohort A-1(Participant Responses - Cycle 1 Day 1)Part A Cohort A-1(Participant Responses - Cycle 1 Day 15)Part A Cohort A-1(Participant Responses - Cycle 2 Day 1)Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 1)Part B Cohort B1 (Caregiver Responses - Cycle 1 Day 15)Part B Cohort B1 (Caregiver Responses - Cycle 2 Day 1)Part B Cohort B1 (Participant Responses - Cycle 1 Day 1)Part B Cohort B1 (Participant Responses - Cycle 1 Day 15)Part B Cohort B1 (Participant Responses - Cycle 2 Day 1)Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 1)Part B Cohort B2 (Caregiver Responses - Cycle 1 Day 15)Part B Cohort B2 (Caregiver Responses - Cycle 2 Day 1)Part B Cohort B2 (Participant Responses - Cycle 1 Day 1)Part B Cohort B2 (Participant Responses - Cycle 1 Day 15)Part B Cohort B2 (Participant Responses - Cycle 2 Day 1)Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 1)Part B Cohort B3 (Caregiver Responses - Cycle 1 Day 15)Part B Cohort B3 (Caregiver Responses - Cycle 2 Day 1)Part B Cohort B3 (Participant Responses - Cycle 1 Day 1)Part B Cohort B3 (Participant Responses - Cycle 1 Day 15)Part B Cohort B3 (Participant Responses - Cycle 2 Day 1)Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 1)Part B Cohort B5 (Caregiver Responses - Cycle 1 Day 15)Part B Cohort B5 (Caregiver Responses - Cycle 2 Day 1)Part B Cohort B5 (Participant Responses - Cycle 1 Day 1)Part B Cohort B5 (Participant Responses - Cycle 1 Day 15)Part B Cohort B5 (Participant Responses - Cycle 2 Day 1)
Very easy to swallow tablet113444646645100212332553011333364689
Easy to swallow tablet212312001433111000112011100000200100
Neither easy nor difficult to swallow tablet000000000010000000100101000000110110
Difficult to swallow tablet000000000000000000000001000000000000
Very difficult to swallow tablet000000000000000000000000000000000100

Adverse events

Collected over Baseline Up To 2.2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A Cohort A11/7 (14.3%)3/7 (42.9%)7/7 (100%)
Part A Cohort A-11/13 (7.7%)5/13 (38.5%)13/13 (100%)
Part B Cohort B10/3 (0%)2/3 (66.7%)3/3 (100%)
Part B Cohort B21/9 (11.1%)0/9 (0%)8/9 (88.9%)
Part B Cohort B31/3 (33.3%)0/3 (0%)3/3 (100%)
Part B Cohort B52/11 (18.2%)4/11 (36.4%)11/11 (100%)
Part C Cohort C10/1 (0%)1/1 (100%)1/1 (100%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPart A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1
Vancomycin infusion reactionSkin and subcutaneous tissue disorders0/70/130/30/90/30/111/1
VomitingGastrointestinal disorders0/71/131/30/90/31/110/1
PyrexiaGeneral disorders0/71/131/30/90/30/110/1
Depressed level of consciousnessNervous system disorders0/70/131/30/90/30/110/1
SeizureNervous system disorders0/71/131/30/90/30/110/1
Febrile neutropeniaBlood and lymphatic system disorders2/71/130/30/90/30/110/1
DiarrhoeaGastrointestinal disorders1/70/130/30/90/30/110/1
Abdominal painGastrointestinal disorders0/70/130/30/90/31/110/1
Upper gastrointestinal haemorrhageGastrointestinal disorders0/70/130/30/90/31/110/1
Respiratory syncytial virus infectionInfections and infestations0/70/130/30/90/31/110/1
Most frequent other events
Showing 10 of 177
Most frequent other events
EventPart A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1
AnaemiaBlood and lymphatic system disorders5/78/131/35/92/37/111/1
NeutropeniaBlood and lymphatic system disorders6/710/132/36/93/38/111/1
ThrombocytopeniaBlood and lymphatic system disorders5/78/132/34/92/39/111/1
AnisocoriaEye disorders0/70/130/30/90/30/111/1
Abdominal painGastrointestinal disorders4/76/131/32/92/34/111/1
DiarrhoeaGastrointestinal disorders7/713/130/35/93/39/110/1
NauseaGastrointestinal disorders5/75/130/32/91/34/111/1
VomitingGastrointestinal disorders6/77/131/36/92/36/111/1
FatigueGeneral disorders1/75/131/32/90/32/111/1
PainGeneral disorders1/70/130/30/90/30/111/1

Baseline characteristics

All participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)Part A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1Total
Mean12.9 ± 3.312.2 ± 3.212.3 ± 4.712.2 ± 4.49.3 ± 3.59.8 ± 4.57.0011.4 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)Part A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1Total
Female262436023
Male571505124
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1Total
Hispanic or Latino02012207
Not Hispanic or Latino772819135
Unknown or Not Reported04100005
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1Total
American Indian or Alaska Native00000000
Asian33010007
Native Hawaiian or Other Pacific Islander00000000
Black or African American00000000
White4728311136
More than one race00100001
Unknown or Not Reported03000003
Region of Enrollment
Region of Enrollment(Participants)Part A Cohort A1Part A Cohort A-1Part B Cohort B1Part B Cohort B2Part B Cohort B3Part B Cohort B5Part C Cohort C1Total
France02000002
Germany21040108
Italy02100003
Japan31010005
Spain2723310027
United States00010012
08

Study locations

25 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • The Regents of the University of California - Los Angeles (UCLA Pediatrics)
    Los Angeles, California 90095-1752, United States
  • Kaiser Permanente Oakland
    Oakland, California 94611, United States
  • Kaiser Permanente Roseville
    Roseville, California 95661, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Spectrum Health
    Grand Rapids, Michigan 49503, United States
  • Cohen Children's Medical Center
    New Hyde Park, New York 11040, United States
  • Atrium Health - Carolinas Medical Center
    Charlotte, North Carolina 28203, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia (CHOP)
    Philadelphia, Pennsylvania 19104, United States
  • Lifespan Cancer Institute
    Providence, Rhode Island 02906, United States
  • Perth Children's Hospital
    Perth, Western Australia 6009, Australia
  • UZ Gent
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Centre Leon Berard
    Lyon, Rhône 69373 CEDEX 08, France
  • Gustave Roussy
    Villejuif, Val-de-Marne 94800, France
  • Institut Curie
    Paris, 75248, France
  • Universitaetsklinikum Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Universitaetsklinikum Essen
    Essen, North Rhine-Westphalia 45122, Germany
  • Charité Campus Virchow-Klinikum
    Berlin, 13353, Germany
  • Fondazione Policlinico Universitario Agostino Gemelli
    Rome, Lazio 168, Italy
  • National Cancer Center Hospital
    Chuo Ku, Tokyo 104-0045, Japan
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona [Barcelona] 8035, Spain
  • Hospital Infantil Universitario Niño Jesús
    Madrid, Madrid, Comunidad de 28009, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2024, 40 months.

Results were first posted in Aug 2025, 1 year 4 months after primary completion.

Of 27 phase 1/2 interventional studies under Sarcoma, Ewing, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 84. This study's 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 23, 2020
StartActual
Nov 9, 2020
Primary completionActual
Mar 15, 2024
CompletionActual
Aug 19, 2025
Results first posted
Aug 6, 2025
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04238819
Responsible party
Sponsor
First posted
Jan 23, 2020
Start date
Nov 9, 2020
Primary completion
Mar 15, 2024
Completion
Aug 19, 2025
Results posted
Aug 6, 2025
Last update
Mar 2, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abemaciclib · Temozolomide

Start the discussion